|
PPARγ LBD (human recombinant)
Cayman Chemical Item Number 10007941
Description
Source:recombinant N-terminal hexahistidine-tagged protein expressed in E. coli · Mr:~34 kDa · The peroxisome proliferator activated receptor (PPAR) family of ligand-activated transcription factors consists of three subtypes encoded by separate genes: PPARα, PPARδ (also referred to as hNUC1, PPARβ, or FAAR), and PPARγ.1↗ Among them PPARγ is the most widely studied and has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis, and cancer.1↗,2↗ Structurally, PPARγ can be described by two primary domains - a ligand binding domain (LBD) and a DNA binding domain (DBD).2↗,3↗ Binding of activating ligands to the LBD promotes heterodimerization with retinoic acid-like receptor (RXR) resulting in the regulated expression of target genes, a significant number of which are related to lipid metabolism.1↗ Select members of the thiazolidinedione class of PPARγ ligands, which includes rosiglitazone and pioglitazone, are currently used for the treatment of insulin resistance associated with type II diabetes.4↗ Cayman’s PPARγ LBD is expressed and purified from E. coli. The purity was determined using gel electrophoresis followed by coomassie staining and western blot analysis using a PPARγ polyclonal antibody. The functionality was tested using a fluorescent ligand binding assay.
Synonyms Peroxisome Proliferator-activated Receptor γ Ligand Binding Domain
Formulation A solution in 50 mM sodium phosphate, pH 7.2, containing 20% glycerol, 150 mM sodium chloride, and 1 mM DTT
Purity ≥90%
Stability 6 months
Storage -80°C
Shipping Dry ice in continental US; may vary elsewhere |